Literature DB >> 11035759

Evidence for vaccine synergy between Borrelia burgdorferi decorin binding protein A and outer surface protein A in the mouse model of lyme borreliosis.

M S Hanson1, N K Patel, D R Cassatt, N D Ulbrandt.   

Abstract

Mice immunized with either the predominantly vector-stage lipoprotein outer surface protein A (OspA) or the in vivo-expressed lipoprotein decorin binding protein A (DbpA) are protected against Borrelia burgdorferi challenge. DbpA-OspA combinations protected against 100-fold-higher challenge doses than did either single-antigen vaccine and conferred significant protection against heterologous B. burgdorferi, B. garinii, and B. afzelii isolates, suggesting that there is synergy between these two immunogens.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11035759      PMCID: PMC97733          DOI: 10.1128/IAI.68.11.6457-6460.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  28 in total

1.  Immunization with outer surface protein (Osp) A, but not OspC, provides cross-protection of mice challenged with North American isolates of Borrelia burgdorferi.

Authors:  W S Probert; M Crawford; R B Cadiz; R B LeFebvre
Journal:  J Infect Dis       Date:  1997-02       Impact factor: 5.226

2.  Borrelia burgdorferi P35 and P37 proteins, expressed in vivo, elicit protective immunity.

Authors:  E Fikrig; S W Barthold; W Sun; W Feng; S R Telford; R A Flavell
Journal:  Immunity       Date:  1997-05       Impact factor: 31.745

3.  Plasminogen is required for efficient dissemination of B. burgdorferi in ticks and for enhancement of spirochetemia in mice.

Authors:  J L Coleman; J A Gebbia; J Piesman; J L Degen; T H Bugge; J L Benach
Journal:  Cell       Date:  1997-06-27       Impact factor: 41.582

Review 4.  Immunological and molecular variability of OspA and OspC. Implications for Borrelia vaccine development.

Authors:  B Wilske; U Busch; V Fingerle; S Jauris-Heipke; V Preac Mursic; D Rössler; G Will
Journal:  Infection       Date:  1996 Mar-Apr       Impact factor: 3.553

5.  Therapeutic passive vaccination against chronic Lyme disease in mice.

Authors:  W Zhong; T Stehle; C Museteanu; A Siebers; L Gern; M Kramer; R Wallich; M M Simon
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-11       Impact factor: 11.205

6.  Borrelia burgdorferi strain-specific Osp C-mediated immunity in mice.

Authors:  L K Bockenstedt; E Hodzic; S Feng; K W Bourrel; A de Silva; R R Montgomery; E Fikrig; J D Radolf; S W Barthold
Journal:  Infect Immun       Date:  1997-11       Impact factor: 3.441

7.  Circumvention of outer surface protein A immunity by host-adapted Borrelia burgdorferi.

Authors:  S W Barthold; E Fikrig; L K Bockenstedt; D H Persing
Journal:  Infect Immun       Date:  1995-06       Impact factor: 3.441

8.  Serum-mediated resolution of Lyme arthritis in mice.

Authors:  S W Barthold; M deSouza; S Feng
Journal:  Lab Invest       Date:  1996-01       Impact factor: 5.662

9.  Assignment of Borrelia burgdorferi strains G25 and VS461 to the Borrelia garinii and Borrelia afzelii genospecies, respectively: a comparison of OspA protein sequences.

Authors:  E Godfroid; A Ben Messaoud; A Poliszczak; Y Lobet; A Bollen
Journal:  DNA Seq       Date:  1995

10.  Borrelia burgdorferi OspA is an arthropod-specific transmission-blocking Lyme disease vaccine.

Authors:  A M de Silva; S R Telford; L R Brunet; S W Barthold; E Fikrig
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

View more
  12 in total

1.  Immunogenicity of Borrelia burgdorferi arthritis-related protein.

Authors:  Sunlian Feng; Emir Hodzic; Kimberly Freet; Stephen W Barthold
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

2.  Conformational nature of the Borrelia burgdorferi decorin binding protein A epitopes that elicit protective antibodies.

Authors:  N D Ulbrandt; D R Cassatt; N K Patel; W C Roberts; C M Bachy; C A Fazenbaker; M S Hanson
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

3.  Species-specific serodiagnosis of Lyme arthritis and neuroborreliosis due to Borrelia burgdorferi sensu stricto, B. afzelii, and B. garinii by using decorin binding protein A.

Authors:  Tero Heikkilä; Ilkka Seppälä; Harri Saxen; Jaana Panelius; Heta Yrjänäinen; Pekka Lahdenne
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

4.  Decorin binding proteins A and B in the serodiagnosis of Lyme disease in North America.

Authors:  Paul M Arnaboldi; Mariya Sambir; Raymond J Dattwyler
Journal:  Clin Vaccine Immunol       Date:  2014-08-13

5.  Allelic variation of the Lyme disease spirochete adhesin DbpA influences spirochetal binding to decorin, dermatan sulfate, and mammalian cells.

Authors:  Vivian M Benoit; Joshua R Fischer; Yi-Pin Lin; Nikhat Parveen; John M Leong
Journal:  Infect Immun       Date:  2011-06-27       Impact factor: 3.441

6.  Antibody-mediated disease remission in the mouse model of lyme borreliosis.

Authors:  Stephen W Barthold; Emir Hodzic; Stefan Tunev; Sunlian Feng
Journal:  Infect Immun       Date:  2006-08       Impact factor: 3.441

Review 7.  Outer membrane proteins of pathogenic spirochetes.

Authors:  Paul A Cullen; David A Haake; Ben Adler
Journal:  FEMS Microbiol Rev       Date:  2004-06       Impact factor: 16.408

8.  An effective second-generation outer surface protein A-derived Lyme vaccine that eliminates a potentially autoreactive T cell epitope.

Authors:  Theresa A Willett; Abbie L Meyer; Eric L Brown; Brigitte T Huber
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-23       Impact factor: 11.205

9.  Molecular adaptation of Borrelia burgdorferi in the murine host.

Authors:  Fang Ting Liang; F Kenneth Nelson; Erol Fikrig
Journal:  J Exp Med       Date:  2002-07-15       Impact factor: 14.307

10.  Borrelia burgdorferi surface protein Lmp1 facilitates pathogen dissemination through ticks as studied by an artificial membrane feeding system.

Authors:  Juraj Koci; Quentin Bernard; Xiuli Yang; Utpal Pal
Journal:  Sci Rep       Date:  2018-01-30       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.